62nd ASH Annual Meeting and Exposition: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I

Oral and Poster Abstracts
Poster

antibodies, apoptosis, Biological, multiple myeloma, cell division, Diseases, Non-Biological, smoldering myeloma, cell regulation, Therapies, chemotherapy, Biological Processes, DNA damage, DNA repair, immune cells, Technology and Procedures, Cell Lineage, immunotherapy, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant, genomics, Myeloid Malignancies, hematopoiesis, flow cytometry, microenvironment, pathways, senescence, signal transduction

1358

Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001

Michael Amatangelo¹^*, Chad Bjorklund¹^*, Jian Kang¹^*, Archana Mukhopadhyay¹^*, María Dolores Jiménez Nuñez²^*, Lilly Wong¹^*, William Pierceall¹^*, Sagar Lonial, MD³, Niels W.C.J. Van De Donk⁴, Rakesh Popat⁵^*, Sundar Jagannath, MD⁶^*, Jeffrey Zonder⁷, Monique C. Minnema⁸, Albert Oriol⁹^*, Jeremy Larsen¹⁰, Ashraf Z. Badros, MD¹¹, Paula Rodriguez-Otero, MD, PhD¹²^*, Pieter Sonneveld, MD, PhD¹³, Tuong Vi Nguyen¹^*, Kevin Hong¹^*, April Sorrell¹^* and Anjan Thakurta¹^*

¹Bristol Myers Squibb, Princeton, NJ
²Celgene Research S.L.U., a Bristol-Myers Squibb Company, Seville, Spain
³Winship Cancer Institute of Emory University, Atlanta, GA
⁴Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands
⁵NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
⁶The Mount Sinai Hospital, New York, NY
⁷Karmanos Cancer Institute, Detroit, MI
⁸Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
⁹Institut de Recerca contra la Leucèmia Josep Carreras and Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain
¹⁰Mayo Clinic, Scottsdale, AZ
¹¹The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD
¹²Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain
¹³Erasmus Medical Center, Rotterdam, Netherlands

1359

Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations

Michael Amatangelo¹^*, Chad Bjorklund¹^*, Peilin Ma¹^*, Krista Wollerman¹^*, William Pierceall¹^*, Sagar Lonial, MD², Niels W.C.J. Van De Donk³, Rakesh Popat⁴^*, Sundar Jagannath, MD⁵^*, Jeffrey Zonder⁶, Monique C. Minnema⁷, Albert Oriol⁸^*, Jeremy Larsen⁹, Ashraf Z. Badros, MD¹⁰, Paula Rodriguez-Otero, MD, PhD¹¹^*, Pieter Sonneveld, MD, PhD¹², Tuong Vi Nguyen¹^*, Kevin Hong¹^*, April Sorrell¹^* and Anjan Thakurta¹^*

¹Bristol Myers Squibb, Princeton, NJ
²Winship Cancer Institute of Emory University, Atlanta, GA
³Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands
⁴NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
⁵The Mount Sinai Hospital, New York, NY
⁶Karmanos Cancer Institute, Detroit, MI
⁷Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
⁸Institut de Recerca contra la Leucèmia Josep Carreras and Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain
⁹Mayo Clinic, Phoenix, AZ
¹⁰The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD
¹¹Clínica Universidad de Navarra, CIMA, IdiSNA, CIBERONC, Pamplona, Spain
¹²Erasmus Medical Center, Rotterdam, Netherlands

1360

Melflufen Shows Efficacy Against Bortezomib-Resistant Multiple Myeloma Models

Konstantin Byrgazov, PhD¹^*, Marianne Kraus²^*, Andrej Besse²^*, Ana Slipicevic¹^*, Fredrik Lehmann¹^*, Christoph Driessen, MD² and Lenka Besse³^*

¹Oncopeptides AB, Stockholm, Sweden
²Department of Oncology and Hematology, Laboratory of Experimental Oncology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
³Department of Oncology and Hematology, Laboratory of Experimental Oncology, Kantonal Hospital St Gallen, St Gallen, Switzerland

1361

The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data

Kylee H Maclachlan, MBChB, PhD¹^*, Binbin Zheng-Lin, MD MSc²^*, Venkata Yellapantula, PhD¹^*, Even H Rustad, MD, PhD¹^*, Benjamin Diamond, MD¹, Malin Hultcrantz, MD, PhD¹, Ahmet Dogan, MD, PhD³, Yanming Zhang, MD⁴, Gareth Morgan, MD, PhD⁵, Ola Landgren, MD, PhD^1,6 and Francesco Maura, MD^1,6

¹Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Perlmutter Cancer Center, New York University Langone Health, New York, NY
⁶Weill Cornell Medical College, New York, NY

1362

A High Throughput Functional Screen Identifies a Novel Apex Inhibitor: Augments Cytotoxicity While Significantly Decreasing Genomic Evolution in Myeloma

Srikanth Talluri, PhD^1,2^*, Jialan Shi, MD, PhD^1,2, Mychell Neptune-Buon^1,2^*, Subodh Kumar, PhD^1,2^*, Lakshmi B. Potluri, MBBS^1,2^*, Nikhil C. Munshi, MD^1,2,3 and Masood A. Shammas, PhD^1,2^*

¹Dana-Farber Cancer Institute, Boston, MA
²VA Boston Healthcare System, Boston, MA
³Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

1363

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

Wassilis S.C. Bruins, MD, MSc¹^*, Wenrou Zheng, MSc¹^*, Jack P. Higgins, PhD²^*, Erin K. Willert, PhD²^*, John Newcomb, PhD³^*, Ajeeta B Dash, PhD³^*, Niels W.C.J. Van De Donk⁴, Sonja Zweegman, MD, PhD⁵ and Tuna Mutis, MD, PhD⁵^*

¹Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands
²Molecular Templates, Inc., Austin, TX
³Takeda Pharmaceuticals International, Cambridge, MA
⁴Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands
⁵Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands

1364

Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Beau M Idler¹^*, Olivia Perez De Acha, MD²^*, Owen Lockerbie, PhD³^*, Ken Flanagan, PhD³^*, Fredrik Lehmann, MSc, PhD³^*, Peter A Forsberg, MD², Tomer M Mark, MD, MS² and Daniel W. Sherbenou, MD, PhD²

¹Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Phoenix, AZ
²Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
³Oncopeptides AB, Stockholm, Sweden

1365

Targeting Bone Marrow Adipose Tissue and the FABP Family Increases Efficacy of Dexamethasone in Multiple Myeloma

Mariah Farrell, BS^1,2^*, Heather Fairfield, MS¹^*, Connor S Murphy, BS^1,3^* and Anastasia D'Amico, BS¹^*

¹Maine Medical Center Research Institute, Scarborough, ME
²University of Southern Maine, Portland, ME
³Graduate School of Biomedical Science and Engineering, University of Maine, Scarborough, ME

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652.P1.24 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I